Rxo (RXO) Common Equity (2021 - 2026)

Rxo (RXO) has 6 years of Common Equity data on file, last reported at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 4.91% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (down 4.91% YoY), and the FY2025 full-year result was $1.5 billion, down 4.4% from the prior year.
• Common Equity for Q1 2026 stood at $1.5 billion, down from $1.5 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.7 billion in Q3 2024 and bottomed at $579.0 million in Q2 2024.
• The 5-year median for Common Equity is $1.1 billion (2022), against an average of $1.1 billion.
• The widest annual swing landed in 2023, when Common Equity tumbled 50.88%; it then surged 180.0% in 2024.
• A 5-year view of Common Equity shows it stood at $587.0 million in 2022, then grew by 1.19% to $594.0 million in 2023, then soared by 171.38% to $1.6 billion in 2024, then dropped by 4.4% to $1.5 billion in 2025, then retreated by 2.08% to $1.5 billion in 2026.
• The last three Common Equity figures came in at $1.5 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.

Peer Comparison